These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16740007)

  • 1. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
    McCormack PL; Wagstaff AJ
    Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro): viewpoints.
    Jutek M; Bachert C
    Drugs; 2006; 66(7):939-40. PubMed ID: 16740008
    [No Abstract]   [Full Text] [Related]  

  • 3. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
    Patel P; Salapatek AM
    Expert Rev Vaccines; 2006 Oct; 5(5):617-29. PubMed ID: 17181436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.
    Drachenberg KJ; Wheeler AW; Stuebner P; Horak F
    Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
    Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW
    Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy.
    Zielen S; Gabrielpillai J; Herrmann E; Schulze J; Schubert R; Rosewich M
    Immunotherapy; 2018 Jun; 10(7):529-536. PubMed ID: 29562801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.
    Rosewich M; Lee D; Zielen S
    Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
    Baldrick P; Richardson D; Woroniecki SR; Lees B
    J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
    Nelson H; Lehmann L; Blaiss MS
    Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis.
    Pfaar O; Lang S; Pieper-Fürst U; Astvatsatourov A; Gerich F; Klimek L; Kramer MF; Reydelet Y; Shah-Hosseini K; Mösges R
    Allergy; 2018 Jan; 73(1):187-195. PubMed ID: 28675499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rush sublingual immunotherapy in Parietaria allergic patients.
    D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
    Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
    Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
    J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents.
    Drachenberg KJ; Heinzkill M; Urban E; Woroniecki SR
    Allergol Immunopathol (Madr); 2003; 31(5):270-7. PubMed ID: 14572416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Six Different Allergen Extracts for Subcutaneous Specific Immunotherapy in Children: An Open-Labelled, Prospective, Controlled Observational Trial.
    Kopp MV; König IR; Friedrichs F; Umpfenbach HU; Niggemann B; Millner-Uhlemann M
    Int Arch Allergy Immunol; 2019; 180(4):284-290. PubMed ID: 31665735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual immunotherapy: allergen specific or placebo effect?
    Kette F; Smith W
    J Allergy Clin Immunol; 2011 Aug; 128(2):430; author reply 430-2. PubMed ID: 21665261
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy.
    Pfaar O; Urry Z; Robinson DS; Sager A; Richards D; Hawrylowicz CM; Bräutigam M; Klimek L
    Allergy; 2012 Feb; 67(2):272-9. PubMed ID: 22107266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.